James Hwang

NATIONAL ZERO-EMISSIONS VEHICLE STRATEGY: Communicating with government officials about the National Zero-Emissions Vehicle Strategy, more specifically (i) providing expert industry input on the strategy, (ii) participating in various advisory groups and (iii) participating in the government review and any future activities related to this topic. These communications will involve discussions about design, infrastructure, incentives, supply, and public awareness. NEW MARKET ENTRANTS: Communicating with government officials about new market entrants into Canada, including ensuring there is a level playing field with automakers regarding the sale and assembly of vehicles in Canada. INTERNATIONAL TRADE: Communicating with government officials about international trade, trade issues and support measures related to the automotive industry and automotive manufacturing, including potential tariffs on automobiles, automotive parts and batteries. GHG REGULATIONS: Communicating with government officials about greenhouse gas regulations and any related consultations with respect to the current or future Canadian standards. COMPETITIVENESS AND ECONOMIC & TRADE UNCERTAINTY: Communicating with government officials about potential support, policies and programs, including but not limited to the Auto Strategy and its pillars, Employment Insurance (EI), preventing labour disruptions (and to re-train employees) and maintain manufacturing competitiveness given the current economic and trade uncertainty. STRATEGIC RESPONSE FUND (SRF) AND STRATEGIC INNOVATION FUND ("SIF"): Communicating with government officials about funding under the Strategic Innovation Fund and the newly created Strategic Response Fund, to ensure and maintain the competitiveness of automobile manufacturing in Canada. REGIONAL ECONOMIC DEVELOPMENT - Communicating with government officials about regional economic development programs and funding, including those offered by the Federal Economic Development Agency. BANK ACT: Communicating with the Government of Canada about the statutory review of the Bank Act, SC 1991, c. 46, more specifically about vehicle leasing. VEHICLE THEFT: Communicating with government officials about vehicle thefts across Canada, including measures to limit vehicle theft. The goal of these communications is, in part, to ensure cross-departmental coordination in addressing the issue. TRAVEL DOCUMENTS: Communicating with government officials about the processing of travel documents, more specifically visas. MOTOR VEHICLE SAFETY ACT: Communicating with government officials about the Motor Vehicle Safety Act, more specifically (i) alignment with American safety standards, (ii) flexibility on regulations for vehicles, (iii) target setting for greenhouse gas emissions and (iv) improved recall completion rates. MEASURES AGAINST FORCED AND CHILD LABOUR: Communicating with government officials about measures to eliminate forced and child labour, more specifically (i) monitoring legislative and regulatory developments to increase supply chain transparency and (ii) ensuring industry has enough time to comply with future supply chain transparency obligations. LUXURY TAX: Communicating with government officials about luxury taxes, more specifically (i) ensuring luxury taxes are removed from electric vehicles ("EVs"), (ii) ensuring luxury taxes are removed (or reduced) on recreational boats and (iii) ensuring luxury taxes do not conflict with other government measures, including reductions in greenhouse gas emissions. INVESTMENT TAX INCENTIVES: Communicating with government officials about investment tax incentives under the Income Tax Act, including the Investment Tax Credit ("ITC"). INTERNATIONAL STUDENT WORK: Communicating with government officials about international students, more specifically eligibility for off-campus work during studies at a designated learning institutions (“DLIs”). ELECTRIC VEHICHLE ("EV") INFRASTRUCTURE: Communicating with government officia

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes. Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG). US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products. The government's Science and Technology strategy as it relates to the biopharmaceutical industry. Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations. Smart Regulations as it relates to the biopharmaceutical industry. Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits. Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization. Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services. Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting. Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products. Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive. Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health. New Substances Notification Regulations as it relates to the biopharmaceutical industry. National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Income Tax Act as it relates to biopharmaceutical products. Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharm

Enacting legislative changes addressing the use of parental alienation and associated pseudo-concepts, so that our justice system can begin protecting women and children without waiting for a slow change in case law precedent. Banning parental alienation accusations in family court. Federal Budget with respect to sustained funding for WAGE and for Women's Rights organizations. Bill C-21: An Act to amend certain Acts and to make certain consequential amendments (firearms), with respect to banning assault-style firearms and domestic/family violence provisions.